Quantcast

Latest Alpha-synuclein Stories

2011-06-14 13:38:51

Researchers at North Carolina State University have figured out how copper induces misfolding in the protein associated with Parkinson's disease, leading to creation of the fibrillar plaques which characterize the disease. This finding has implications for both the study of Parkinson's progression, as well as for future treatments. The protein in question, alpha-synuclein, is the major component of fibrillar plaques found in Parkinson's patients. Researchers had already discovered that...

2011-04-04 19:52:37

As Parkinson's Awareness Month gets underway, a Canadian-led international study is providing important new insight into Parkinson's disease and paving the way for new avenues for clinical trials. The study, led by Dr. Michael Schlossmacher in Ottawa, provides the first link between the most common genetic risk factor for Parkinson's and the hallmark accumulation of a protein called alpha-synuclein within the brains of people with Parkinson's. It is published in the most recent edition of the...

2011-02-28 15:53:31

A protein pathway that may hold the secret to understanding Parkinson's disease has been discovered and explained by Iowa State University researchers. Anumantha Kanthasamy, a distinguished professor of biomedical sciences and the W. Eugene and Linda R. Lloyd Endowed Chair in Neurotoxicology at the ISU College of Veterinary Medicine, has been working to understand the complex mechanisms of the disease for more than a decade. He believes this recent discovery offers hope for the cure. The...

76c0c5dac3d71e76a09fc54d9f0fc864
2011-02-11 08:24:31

Investigators Build a Case Linking Chemical DOPAL to Illness In new research from Saint Louis University, investigators have found evidence that a toxin produced by the brain is responsible for the series of cellular events that lead to Parkinson's disease. The study, published in PLoS One, found that the brain toxin DOPAL plays a key role in killing the dopamine neurons which trigger the illness. In earlier research, Saint Louis University investigators found that DOPAL seemed to be...

2011-02-09 01:05:18

The findings may enable scientists to better understand the molecular biology and biophysics of the brain and diseases such as Alzheimer's and Parkinson's A team of scientists from The Scripps Research Institute and the University of California, San Diego (UCSD) have developed a novel technique to observe previously unknown details of how folded structures are formed from an intrinsically disordered protein. The insights could help scientists to better understand the mechanism of plaque...

2011-01-19 14:45:22

Breakthrough suggests damaged proteins travel between cells The study, published in the Journal of Clinical Investigation, reveals that damaged alpha-synuclein proteins (which are implicated in Parkinson's disease) can spread in a 'prion-like' manner, an infection model previously described for diseases such as BSE (mad cow disease). "This is a significant step forward in our understanding of the potential role of cell-to-cell transfer of alpha-synuclein in Parkinson's disease pathogenesis...

2011-01-03 21:12:55

Study is first to pinpoint the precise anatomical location where vision loss appears to occur in glaucoma In a study published today in the Proceedings of the National Academy of Sciences (Early Edition ahead of print), a team of researchers from the Kennedy Krieger Institute and four collaborating institutions, identified a new and unexpected biological pathway that appears to contribute to the development of glaucoma and its resulting vision loss. Prior research has suggested that the optic...

2010-12-16 11:21:00

VIENNA, December 16, 2010 /PRNewswire/ -- With a grant of USD 475,000, the Michael J. Fox Foundation is funding preclinical development of a vaccine against Parkinson's disease by AFFiRiS AG. The vaccine, known as PD01, targets the protein alpha-synuclein and might offer for the first time a possibility for a treatment that can slow or stop the progression of Parkinson's disease. The basis of PD01 is the company's AFFITOME(R) technology, which already delivered, among others, two vaccines...

2010-12-08 08:00:00

CRANBURY, N.J., Dec. 8, 2010 /PRNewswire/ -- Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company focused on developing treatments for rare diseases, today announced that it has been awarded a second grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) for the development of a novel, next-generation pharmacological chaperone for the treatment of Parkinson's disease. The $500,000 award will be distributed over a period of 24 months. Amicus' studies will be...

2010-11-17 17:34:55

Researchers describe their scientific presentations for neuroscience 2010 Researchers from Georgetown University Medical Center's departments of neuroscience, pharmacology, physiology, biochemistry, molecular and cellular biology, and the interdisciplinary program of neuroscience will present more than 50 research abstracts at the 40th Annual Meeting of the Society for Neuroscience Nov. 13th through the 17th in San Diego. Modulation of temporal relationships between default mode and...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related